Markowitz Wins Prestigious Hamdan International Award for Medical Research Excellence
 |
|
|
Sanford Markowitz
|
Sanford Markowitz, MD, PhD is the
winner of the Hamdan International Award for Medical Research Excellence for the topic of Colon Disorders
, given by the Sheikh Hamdan bin Rashid al Maktoum Award for Medical Sciences.
According to an official announcement provided by the award, Markowitz was selected for the prestigious award for his expertise as a medical oncologist and colon cancer researcher who is internationally recognized for his discovery of two key colon cancer suppressor genes, TGF-beta RII and 15-PGDH. Additional achievements include showing RII mutations explain how cancers develop in DNA repair deficient cells such as in Lynch syndrome, developing 15-PGDH inhibitor drugs as therapeutics for tissue regeneration, and pioneering molecular tests of stool DNA for early colon cancer detection.
H.H. Sheikh Hamdan bin Rashid al Maktoum, Deputy Ruler of Dubai, the UAE Minister of Finance and the Patron of the Award, will honor Markowitz and the other winners in a prestigious ceremony to be held in Dubai, United Arab Emirates, on December 14, with personalities and organizations from UK, France, Australia, United Arab Emirates, Saudi Arabia, and Morocco.
Markowitz is the Sanford D. Markowitz / Frances Wragg Ingalls Professor of Cancer Genetics in the Department of Medicine at the CWRU School of Medicine, Co-Leader of the GI Cancer Genetics Program at the Case Comprehensive Cancer Center, and Principal Investigator of the Case Specialized Program of Research Excellence in Gastrointestinal Cancers (GI SPORE).
more>
|
Mark Chance, vice dean for research, named AAAS fellow
|
|
|
Mark Chance
|
Mark R. Chance, PhD, vice dean for research at Case Western Reserve University School of Medicine and member of the Case Comprehensive Cancer Center, has been
named a fellow of the American Association for the Advancement of Science. Election as a fellow is an honor bestowed upon AAAS members by their peers. AAAS is the world's largest general scientific society and publisher of the journal Science.
Chance, elected to the AAAS section on chemistry, was cited "[f]or distinguished contributions in the fields of structural biology and chemistry by advancing technologies of mass spectrometry approaches for the study of protein structure and dynamics." His research interests include cellular signaling and transport by membrane proteins and new biophysics approaches for drug development.
more>
|
| CULTURAL COMPETENCY SERIES |
|
Southeastern Health Equity Council Cultural Competency Resource Guide and White Paper
From U.S. Department of Health and Human Services: Office of Minority Health; web-posting from Oct 10, 2016
The Southeastern Health Equity Council's (SHEC) Cultural Competency Committee has two useful publications posted on its website.
"Cultural Competency: What is it and Why is it Necessary?" is a white paper defining "cultural competency" and explaining its importance and need in the alleviating issues of disparities within health care systems. Commonly used terms and concepts are explored in this paper. The "Cultural Competency Resource Guide" is a guide to resources, trainers, institutions, and publications about cultural and linguistic competency that we can share with our members, stakeholders and partners to help address cultural barriers with our health care systems.
The
SHEC
is one of 10 regional health equity councils formed in 2011 as a part of the National Partnership for Action to End Health Disparities (NPA). The NPA is a national movement with the mission to improve the effectiveness of programs that target the elimination of health disparities through coordination of leaders, partners and stakeholders that are committed to action.
|
NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
The National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and
supportive care areas.
The Annual Conference General Session begins on Thursday, March 23 at 8:00 AM and concludes on Saturday evening, March 25. This year's agenda will include more than 25 educational sessions featuring the latest advances in oncology care, plus interactive patient case studies & roundtable discussions.
This conference (with the exception of the NCCN Roundtable Discussions) will be designated for AMA PRA Category 1 Credit™ for physicians and certified for credit for nurses and pharmacists.
Registration Waiver/Discounts for NCCN Member Institutions
Registration fee is waived for NCCN Member Institution junior faculty (with a title of Assistant Professor or below). NCCN also extends a 50% discount off the registration fee to staff employed at NCCN Member Institutions. Interested individuals should e-mail Liz Rieder at [email protected] to learn more about how to apply for these discounts.
|
Modern Healthcare - Nov 26, 2016
It also gives patients greater access to clinical trials that test experimental medicines. According to Dr. Stan Gerson, president of the Association of American Cancer Institutes and director of the Case Comprehensive Cancer Center and UH Seidman Cancer Center, the proportion of patients involved in clinical trials ranges from about 2% to 3% in large community-based practice groups to 8% to 10% at most comprehensive cancer centers with the most highly specialized academic facilities enrolling as many as 20% of their patients in trials. "
That's a tenfold range of the opportunity for a patient to participate in a clinical trial, which is huge," Gerson said. "We know that patients really do benefit from early-phase as well as late-phase clinical trials," he added, although he cautioned against generalizations about the benefits of these trials for a disease as complex as cancer.
|
Ideas: Councilman Matt Zone's New Appointment; Complicated Grief; Moonshot
ideastream - Nov 22, 2016
Stan Gerson, the director of the Case Comprehensive Cancer Center and UH Seidman Cancer Center, discuss the future of the cancer moonshot. |
Cure Magazine - Nov 23, 2016
Halle Moore, MD, Case Comprehensive Cancer Center, medical oncologist at the Cleveland Clinic, discusses the negative symptoms many breast cancer survivors face, and the treatments that these symptoms were associated with.
|
OncLive - Nov 21, 2016
Manmeet Ahluwalia, MD, FACP, Case Comprehensive Cancer Center, Miller Family Endowed Chair in Neuro-Oncology and Head of Operations, Burkhardt Brain Tumor NeuroOncology Center, discuses a new classification system for brain metastases.
|
ideastream - Nov 21 2016
Stress is a predictor of early mortality - too much stress and you take years off of your life, said
Dr. Monica Hooper, director of the Office of Cancer Disparities Research at the Case Comprehensive Cancer Center. Discrimination and it's link to stress is pervasive and it's real, she added.
"You know one thing I always say to people is if you have multiple people in a community but they are all reporting a similar phenomenon how can we deny that it's real? How can we invalidate that person's experience? That's another factor that adds to the stress of individuals when they are repeatedly sharing their story and it is invalidated, it is ignored or it is told that this is just not happening," she said.
Many African Americans suffer from very high levels of chronic stress which over time exacts an emotional and physical toll. This can lead to other health problems such as heart disease and cancer, she said.
|
Limited Submission Opportunities for Pilot Projects for Childhood Brain Tumors
DEADLINES: Letter of Intent: Nov 30
Requests for Full Applications: Dec 14
Submission of Full Applications: Jan 16, 2017
With support from the Prayers from Maria Children's Glioma Foundation, the Case Comprehensive Cancer Center is
providing seed funding for the support of projects focused on developing cures for pediatric and adolescent/young adult gliomas within the Center. Brain tumors are the second most common cancer in children, with an estimated 4,620 cases being diagnosed in children and adolescents in the US in 2015. Gliomas are the most aggressive of these tumors, are associated with poor outcomes, and have limited treatment options. The goal of this RFA is to support pilot projects that will impact outcomes for pediatric and adolescent/young adult patients with gliomas.
Funds from this RFA will be restricted to research proposals that address pediatric and adolescent/young adult gliomas with the expectation that insights from these awards will lead to new diagnostics, prognostics, and/or therapeutics. It is also expected that the research projects funded by this RFA will lead to nationally competitive grant proposals from multi-investigator teams.
|
Limited Submission: W.M. Keck Foundation
Internal LOI Deadline: Dec 16
External Deadline: May 1, 2017
The W.M. Keck Foundation Research Program seeks to benefit humanity by funding fundamental, high-risk research in two specific areas: 1) medical research and 2) science and engineering. Both Senior and Early Career investigators are encouraged to apply. CWRU may submit two proposals per funding cycle: one (1) in Medical Research and one (1) in Science and Engineering Research.
Applicants are encouraged to consult with their Associate Deans for Research prior to internal submission to assure they meet eligibility criteria and their projects meet stated program objectives.
|
AACR Clinical and Translational Cancer Research Fellowship
Deadline: Jan 10, 2016
The AACR Clinical and Translational Cancer Research Fellowship represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct clinical and/or translational cancer research and to establish a successful career path in this field. The research proposed for funding may be translational or clinical in nature.
Grant recipient must attend the Grants Reception and Dinner (April 4, 2017), held during the AACR Annual Meeting 2017, and formally accept the grant. Grant funds may be used to support the grantee's registration and attendance at this Annual Meeting.
|
Doris Duke Charitable Foundation
Deadline: Jan 24, 2017
The Doris Duke Charitable Foundation
is accepting applications for its Clinical Research Mentorship program.
The annual program provides previously funded Doris Duke investigators the opportunity to foster the next generation of clinical researchers by mentoring a medical student for a year. Through the program, past and present principal investigators on medical research grants from DDCF identify a medical student to mentor for a year and then apply with that student as a team. Alternatively, medical students identify a qualifying DDCF principal investigator and apply together. In either case, the DDCF principal investigator must be the applicant.
Each mentee must be willing to take twelve months out from medical school, typically after the third year of school. Teams will receive $70,400 over a year, inclusive of a $30,000 stipend for the student. The student's year out will start in the summer of 2017 and end in the summer of 2018. DDCF expects to make awards to ten mentor/mentee teams in 2017.
To be eligible, mentees must be students in good standing at any U.S.-based medical school working on an M.D. or D.O. Mentors must be DDCF researchers funded through the following programs: Clinical Scientist Development Awardees 1998-2015, Distinguished Clinical Scientist Awardees since 1999, or Innovations in Clinical Research.
|
NIH BULLETIN- Notices and Funding Opportunities
|
|
|
FOLLOW US
|
|
Thurs, Dec 1
Developmental Therapeutics Journal Club
"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes"
[N Engl J Med 2016;375:2023-36]
9a R4-027 Cleveland Clinic
Neurosciences Seminar
John Bethea, PhD
Drexel University
"The Yin and Yang of Tumor Necrosis Factor (TNF) in CNS Injury and Repair"
12:10p BRB 105
Molecular Biology and Microbiology Seminar
1p SOM W203
|
|
Fri, Dec 2
Hem/Onc Fellows
8a Breen Conf Rm
Cancer Center Seminar Series
Matthew Vander Heiden, MD, PhD
Eisen and Chang Associate Professor, Koch Institute for Integrative Cancer Research , Department of Biology , Massachusetts Institute of Technology; Instructor, Medicine
Dana-Farber Cancer Institute and Harvard Medical School
12p BRB 105
Radiation Oncology Grand Rounds
Nicole Simone, MD
Margaret Q. Landenberger Associate Professor, Radiation; Director, Jefferson Breast Center; Co-Leader, Breast Cancer Research Program, Thomas Jefferson University
"Diet modification as a novel therapeutic for cancer treatment: When less is more"
12p Lerner B-151
|
|
Mon, Dec 5
Genomic Medicine Institute Seminar
Madhav Sankunny
Eng Lab, Genomic Medicine, Cleveland Clinic
"Role of KLLN in DNA Damage Response (DDR) and Apoptosis"
12:30p NE1-205 Cleveland Clinic
Tumor Immunology and Immunotherapy Group
Nicole Steinmetz, PhD
Associate Professor, Biomedical Engineering, CWRU
4p WRB 3-136
|
|
Tues, Dec 6
Pathobiology Seminar Series
Mark Peeples, PhD
Professor, Pediatrics and Molecular & Cellular Biochemistry, Ohio State University
"Binding and Entering: Who's in Charge for Respiratory Syncytial Virus"
11:30a NC1-202 Cleveland Clinic
Cancer Biology Seminar Series
Hannah Picariello, MS, Graduate Student, Rosenfeld Lab, Cancer Biology, Cleveland Clinic
"Go or Grow: Loss of Nonmuscle Myosin IIA in GBM Blocks Tumor Invasion and Enhances Proliferation"
2p NC1-202 Cleveland Clinic
|
|
Wed, Dec 7
Hem/Onc Div Res Conf
8a Lerner B-151
Immunology Invited Speaker Seminar Series
Tara DeSilva, PhD
Associate Staff, Neurosciences, Cleveland Clinic
"The Role of the Myeloid Lineage in Myelin Development and Myelin Destruction"
12p NC1-202 Cleveland Clinic
|
|
Thurs, Dec 8
Dermatology Grand Rounds
Radhika Atit, PhD
Associate Professor, Biology, CWRU
9:30a BRB 105
Neurosciences Seminar
Adam Carter, PhD
Associate Professor, Center for Neural Science, New York University
12p BRB 105
Molecular Biology and Microbiology Seminar
1p SOM W203
Prostate Cancer Working Group Seminar Series & Journal Club
Todd Morgan, MD
Associate Professor, Urology, University of Michigan
"Liquid biopsy approaches in early and late stage prostate cancer"
3p NE1-205 Cleveland Clinic
|
|
Fri, Dec 9
Hem/Onc Fellows
8a Breen Conf Rm.
Neurology Grand Rounds Special Presentation
Michael Glantz, MD
Pennsylvania State Milton S. Hersey Medical Center
"Update in Leptomeningeal Metastasis"
8a Kulas Auditorium 5th Floor, Lakeside Building
Cancer Center Research in Progress Seminar
4p WRB 3-136
|
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
Mar 23-25, 2017
GvHD National Symposium
Oct 13, 2017
Grand Event Center, Columbus, OH
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Deadline:
Dec 1
Deadline: Jan 13, 2017
LOI Deadline: Feb 1, 2017
Invited Full Proposal Deadline: Mar 15, 2017
LOI Deadline:
Feb 1, 2017
Deadline: Open
Deadline: Open
Deadline: Open
|
|
 |
|
